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Myelodysplastic syndrome (MDS) is a clonal stem-cell disorder characterized by dyshematopoiesis. We
report a patient who presented with cytopenias and microangiopathic hemolytic anemia. Chromosome
microarray analysis (CMA), using single nucleotide polymorphism arrays, on peripheral blood revealed
genomic imbalances indicative of MDS, which was conﬁrmed by bone marrow examination. This report
highlights the importance of suspecting MDS in patients with cytopenias and microangiopathic hemo-
lytic anemia. CMA of peripheral blood may assist in the preliminary diagnosis of MDS, representing a
comparatively less invasive diagnostic procedure and may aid bone marrow evaluation when an aspirate
sample is insufﬁcient for conventional cytogenetic analysis.
& 2016 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Myelodysplastic syndrome (MDS) is an acquired, clonal stem-
cell disorder characterized by dyshematopoiesis and stem-cell
dysplasia of single or multiple blood cell lineages. MDS leads to
varying degrees of cytopenias and, paradoxically, hypercellular
bone marrow with potential evolution to acute myeloid leukemia
(AML) or marrow failure [1–3]. As a result of dyserythropoiesis, red
blood cell (RBC) morphological abnormalities, such as anisocytosis,
poikilocytosis, macrocytosis and sometimes elliptocytosis, are of-
ten observed in MDS [1,2]. Schistocytes refer to fragmented RBCs
and are commonly associated with causes of microangiopathic
hemolytic anemia (MAHA). However, schistocytosis with a high
reticulocyte count in the peripheral blood smear is a rare and
unusual manifestation of MDS [1].
Karyotypic analysis is commonly used in the diagnostic work up
of various hematological diseases. Some chromosome abnormalities
are speciﬁcally associated with certain diseases or disease subtypes
[4,5]. The detection of various chromosomal alterations not only as-
sists in diagnosis, but also helps in the prognostication of patients [6].
However, due to technical limitations, such as the need for sufﬁcient
number of dividing malignant cells and the limited resolution of lightn open access article under the C
imi).microscopy, karyotypic analysis is able to detect such abnormalities
in only about 50% of MDS cases [7].
Whole genome scanning technologies, such as chromosomal
microarray analysis (CMA), using single nucleotide polymorphism
(SNP) arrays, do not require dividing cells, have a much greater
resolution than karyotypic analysis, and allow for detection of loss
of heterozygosity (LOH) as well as changes in genomic copy number
[7]. SNP-based CMAs also permit the detection of acquired copy-
neutral LOH (cn-LOH), which is common in hematological malig-
nancies [8], but undetectable by conventional cytogenetics [7,9].
Here we describe severe anemia and marked schistocytosis as a
manifestation of MDS in an elderly patient admitted at our cancer
center. Initial bone marrow examination was inadequate for de-
tailed histopathological evaluation and cytogenetics. However,
application of SNP-based CMA on peripheral blood uncovered
genomic imbalances indicative of MDS, which was conﬁrmed
upon a subsequent bone marrow examination.Materials and methods
CMA was performed essentially as described in detail else-
where [10]. Brieﬂy, total genomic DNA from blood was digested
with NspI restriction enzyme, ligated with an adaptor compli-
mentary to polymerase chain reaction (PCR) primer, PCRC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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beled, and hybridized to an Affymetrix CytoScan HD array. The
hybridized array was washed and scanned with a GeneChip
Scanner 3000 7G. Intensities of probe hybridization were analyzed
using Affymetrix GeneChip Command Console, and copy number
and genotyping analyses were performed using Affymetrix Chro-
mosome Analysis Suite software.Case summary and results
A 70-year-old woman was admitted with a 2-month history of
exertional dyspnea associated with weakness and fatigue, de-
creased appetite and weight loss. Her complaints had been wor-
sening during the previous 2 weeks, and she had also noticed
purple lesions on both knees at that time. She denied any history
of hematemesis, hemoptysis, melena, hematochezia or hematuria.
Past medical history was signiﬁcant for right-sided triple negative
breast cancer, treated by lumpectomy followed by local radiation
therapy 11 years prior to this encounter. She also had a history of
stage 1A uterine cancer, for which she underwent total abdominal
hysterectomy with bilateral salpingo-oophorectomy, followed by
3 cycles of chemotherapy with carboplatin and paclitaxel with ra-
diation therapy to the pelvis 3 years prior to this visit.
Physical examination showed no apparent distress. Other than
conjunctival pallor and palpable purpuric lesions on both knees,
no bruises or petechiae were noted on any other part of her body.
The rest of the systemic examinations were unremarkable.
Blood work on presentation showed pancytopenia (hemoglobin:
6.2 g/dL, leukocytes: 3.5109/L and platelets: 57109/L) with re-
ticulocyte count of 10.15% and hyperbilirubinemia with signiﬁcant
schistocytosis, elliptocytosis, tear drop cells and basophilic stippling,Fig. 1. A) Peripheral blood ﬁlm showing marked schistocytosis, anisocytosis and nucleat
biopsy with severe crush artifacts. C) Bone marrow biopsy with severe crush artifacts sabnormal immature myeloid cells, hyposegmented hypogranular
neutrophils and abnormal nucleated RBCs (Fig. 1A), pointing towards
hemolysis. A work up for hemolytic anemia was ordered. Her blood
counts had continued to fall. Her coagulation work up was normal.
Direct and indirect Coombs tests were negative. Bilirubin was in-
creased to 3.7 mg/dL, with normal direct bilirubin and normal liver
enzymes. LDH 683 U/L, haptoglobinwas o10mg/dL, and her ESR was
100 mm. Serum folate, B12, iron and total iron binding capacity were
within normal limits. Erythropoietin was elevated: 49.9 mU/mL. Chest
and abdominal CT of lungs and liver ruled out metastasis from pre-
vious malignancies that could account for shortness of breath and
elevated bilirubin levels. Paroxysmal nocturnal haemoglobinuria was
also excluded based on normal CD55 and CD59 expression on ﬂow
cytometry.
Initial bone marrow biopsy was inadequate in size for detailed
examination and had severe crush artifact. The preserved focus of
marrow showed hypercellularity with large, multinucleated, dys-
plastic megakaryocytes and megaloblastoid changes in erythroid
series (Fig. 1B and C). There was no increase in reticulin ﬁber
content in the marrow biopsy, making a myelophthisic process as
the underlying cause of schistocytosis unlikely. Blood vessels were
not appreciated in the bone marrow biopsy due to severe crush
artifact. A skin biopsy showed deep subcutaneous hemorrhage and
no evidence of microangiopathic changes. The marrow aspirate
was also insufﬁcient for further analysis by ﬂow cytometry or
cytogenetics. CMA of peripheral blood revealed multiple genomic
imbalances in a mosaic state, including losses of portions of
chromosome arms 5q, 7q and 13q, isodisomy of 17p, and gains of
chromosomes/chromosomal segments 1p, 5p, 6, 8, 19, 20p, 21
(Fig. 2), ﬁndings consistent with the diagnosis of MDS. Conven-
tional cytogenetic analysis performed on a repeat bone marrow
sample revealed an abnormal karyotype: 47-50,X,-X,der(?)t(?;1)ed red blood cells as well as myelocytes and dysplastic neutrophils. B) Bone marrow
howing cluster of dysplastic megakaryocytes.
Fig. 2. Chromosomal microarray analysis showing multiple genomic imbalances in a mosaic state, including losses of 13q12.3q14.11 and portions of chromosome arms 5q
and 7q, as well as gains of chromosomes or chromosome segments 1p, 5p, 6, 8, 19, 20p, and 21 as well as isodisomy of 17p.
M.F. Zahid et al. / Leukemia Research Reports 5 (2016) 23–26 25(?;q21),þadd(1)(q12)x2, del(5)(q14),þ6,add(7)(q22),þ8,þ9,13,
þ19,20,þ21,þ0-2mar[cp15]/46,XX. The ﬁndings were similar to
those of the peripheral blood CMA and conﬁrmed the diagnosis of
therapy-related MDS with complex cytogenetics.Discussion
This is a case report of therapy-associated MDS and MAHA, a
rare manifestation of MDS. The initial presentation was low pla-
telet count and anemia, elevated bilirubin and schistocytosis in the
peripheral blood smear. The patient presented with non-immune
hemolytic anemia. Hemolytic anemias are common occurrences in
patients with hematologic malignancies, particularly AML and
chronic myeloid leukemia (CML), but are rarely observed in MDS,
with only a few cases reported in the literature [11].
Abnormal RBC morphologies have previously been reported in
cases of MDS. These include elliptocytosis [1,2,12], spherocytosis
[13], acanthocytosis [14] and basophilic stippling [1–3]. However,
marked schistocytosis by itself is rare. To the best of our knowledge,
only 3 cases of schistocytosis with underlying MDS have been re-
ported in the English literature [1,12]. In 1984, Hartz et al. reported
a 78-year-old man who presented with refractory anemia with
peripheral schistocytes [12]. The patient was subsequently diag-
nosed with MDS upon further work up. Rummens et al. described
two cases of MDS (ages 59 and 60) who presented with schisto-
cytosis on peripheral blood ﬁlm [1]. Schistocytosis has also been
reported in other malignant hematologic disorders. For example,
Atkins and Muss described a series of 12 patients with ery-
throleukemia [13]. All of their patients had evidence of schistocy-
tosis and elliptocytosis in peripheral blood. RBC fragmentation hasbeen described as a general observation in patients with leukemia
[13,15]. Our patient showed other morphologic abnormalities of
RBCs, including occasional elliptocytes and basophilic stippling,
which are commonly observed with MDS [1–3].
Karyotypic analysis has been invaluable for detection of chro-
mosomal rearrangements speciﬁc to certain diseases, such as t
(9;22) in CML and t(15;17) in acute promyelocytic leukemia [4,5],
and can predict sensitivity to molecularly targeted drugs, such as
imatinib in CML [16]. Cytogenetics have been part of the revised
International Prognostic Scoring System (IPSS-R) and shown to
have important prognostic implications in MDS patients, with
detection of 5q- syndrome being a prominent example [6].
Whole genome scanning studies, such as CMA using SNP ar-
rays, eliminate the need for dividing cells, have a much higher
level of resolution than karyotypic analysis, and allow for detec-
tion of both DNA copy number and LOH throughout the genome in
a single experiment [7]. CMA also uncovers acquired cn-LOH,
which is indicative of somatic uniparental isodisomy. While cn-
LOH occurs commonly in hematological malignancies [8], it is
undetectable by classical cytogenetics [7,9]. Such was the case in
our patient, in which CMA of peripheral blood demonstrated iso-
disomy of 17p, a site encompassing the TP53 tumor suppressor
gene. Notably, recurrent mutations of TP53 have been previously
described in myeloid malignancies [8].
While this report demonstrates that CMA with SNP arrays is
useful for the analysis of genomic imbalances in the peripheral
blood of patients with suspected MDS, this technique is not readily
available at many medical centers and many institutions perform
ﬂuorescence in situ hybridization to detect cytogenetic abnormal-
ities. Hence, it is important to consider/discuss other diagnostic
methods which can utilize peripheral blood (such as high-
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analysis based on Sanger sequencing, PCR, and next-generation
sequencing (NGS) technologies has been introduced in many cen-
ters and is able to detect MDS-related mutations in bone marrow
and may be used to advance classiﬁcation and prognostication of
MDS. In recent years, the ﬁeld of molecular diagnostics has been
signiﬁcantly advanced with the introduction of NGS. There are now
multiple commercially available NGS assays, each with a unique
method of template preparation, sequencing and imaging and dif-
ferent approaches for the analysis of data [18–20].
In conclusion, our case highlights the importance of consider-
ing a diagnosis of MDS in a patient with cytopenias and MAHA,
especially in the presence of predisposing factors such as prior
chemotherapy and radiation therapy. Our studies indicate that
CMA analysis of peripheral blood can assist in the initial diagnosis
of MDS. Peripheral blood CMA can be a useful investigation if MDS
is suspected, representing a comparatively less invasive diagnostic
procedure that may precede bone marrow examination. Pro-
spective studies with large sample sizes will help determine its
sensitivity and speciﬁcity as a potential ‘screening test’ in the di-
agnostic workup of patients suspected to have MDS.Author contributions
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